Ronald H. Goldstein, MD

Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Our laboratory is exploring the regulation of the alveolar matrix during the development of early emphysema and fibrosis. The loss of matrix substances results in emphysema whereas the excessive deposition of matrix substances results in pulmonary fibrosis. Employing the techniques of cellular and molecular biology, we are developing methods to modulating the levels of collagen, elastin and other key matrix substances in the alveolar wall. These approaches are studied in wild type and transgenic murine models of emphysema and fibrosis.

We have extensive experience in the diagnosis and management of individuals with pulmonary fibrosis. In human studies, our clinical experimental interest involves the use of novel substances to treat idiopathic pulmonary fibrosis (IPF). We participate in several clinical studies to evaluate the efficacy of these agents in the pathogenesis of IPF.

Research special interests include: Pulmonary Matrix Biology related to Pulmonary Fibrosis and Emphysema

Clinical special interests include: Pulmonary Fibrosis

Publications

  • Published 12/20/2025

    Colucci RL, Garshick E, White J, Wan ES, O'Leary J, Blake LA, Hoyt SM, Johnston D, LaCerda K, Morreale-Karl M, Jati A, Wilder FG, Wiener DC, Rucci JM, Goldstein RH. Identification and management of incidental findings in a Veteran's lung cancer screening program. Respir Res. 2025 Dec 20; 27(1):24. PMID: 41421986.

    Read at: PubMed

  • Published 5/20/2024

    Johnson SW, Wang RS, Winter MR, Gillmeyer KR, Zeder K, Klings ES, Goldstein RH, Wiener RS, Maron BA. Cluster analysis identifies novel real-world lung disease-pulmonary hypertension subphenotypes: implications for treatment response. ERJ Open Res. 2024 May; 10(3). PMID: 38770008.

    Read at: PubMed

  • Published 4/20/2024

    Miller MS, Johnson SW, Opotowsky AR, Landzberg MJ, Sharma NS, Goldberg HJ, Wong AK, Witkin AS, Rodriguez-Lopez J, Goldstein RH, Maron BA, Wertheim BM. Iatrogenic esophageal dysmotility as a barrier to transplantation in pulmonary arterial hypertension. JHLT Open. 2024 Aug; 5:100098. PMID: 40143909.

    Read at: PubMed

  • Published 7/1/2022

    Johnson SW, Finlay L, Mathai SC, Goldstein RH, Maron BA. Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing. Pulm Circ. 2022 Jul; 12(3):e12126. PMID: 36092795.

    Read at: PubMed

  • Published 3/14/2022

    Maron BA, Choudhary G, Goldstein RL, Garshick E, Jankowich M, Tucker TJS, LaCerda KA, Hattler B, Dempsey EC, Sadikot RT, Shapiro S, Rounds SI, Goldstein RH. Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial. Pulm Circ. 2022 Jan; 12(1):e12043. PMID: 35506072.

    Read at: PubMed

View All 96 Publications:   View Full Profile in BUMC

Other Positions

  • Research Assistant Professor, Biochemistry & Cell Biology
    Boston University Chobanian & Avedisian School of Medicine
  • Member, Pulmonary Center
    Boston University
  • Graduate Medical Sciences Educator and Mentor (Primary Mentor of Graduate Students)
    Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

Websites

Education

  • SUNY Downstate Medical Center, MD
  • University of Wisconsin Madison, BS

View all profiles